Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
McKesson
Covington
Fish and Richardson
Cipla
Farmers Insurance
Chubb
AstraZeneca
Fuji

Generated: June 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,450,299

« Back to Dashboard

Summary for Patent: 8,450,299
Title:Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
Abstract: The present invention provides ascending-dose extended cycle regimens in which a female is administered an estrogen and a progestin for a period of greater than 30 or 31 consecutive days, optionally followed by a hormone-free period or by a period of administration of estrogen. The disclosed regimens can be administered to a female to provide contraceptive and non-contraceptive benefits.
Inventor(s): Diliberti; Charles E. (Montclair, NJ), Reape; Kathleen Z. (Bryn Mawr, PA), Bronnenkant; Lance J. (Snyder, NY)
Assignee: Teva Womans's Health, Inc. (Woodcliff Lake, NJ)
Application Number:13/492,138
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,450,299
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,450,299

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Teva Branded Pharm QUARTETTE ethinyl estradiol; levonorgestrel TABLET;ORAL 204061-001 Mar 28, 2013 AB RX Yes Yes ➤ Sign Up ➤ Sign Up PREVENTION OF PREGNANCY ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,450,299

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,415,332 Methods of hormonal treatment utilizing ascending-dose extended cycle regimens ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Federal Trade Commission
Dow
Deloitte
Medtronic
US Department of Justice
Daiichi Sankyo
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.